GovWire

Guidance: COVID-19: letter to clinically extremely vulnerable people

Public Health England

January 12
17:36 2021

Letter to clinically extremely vulnerable people from Matt Hancock and Robert Jenrick

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email publications@phe.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter to clinically extremely vulnerable people from Matt Hancock and Robert Jenrick (large print)

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email publications@phe.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

If you or your child has been identified as clinically extremely vulnerable, you will receive a letter from the Government addressed personally to you. This letter is to let you know about the guidance that is in place for clinically extremely vulnerable people during the national lockdown.

Published 13 November 2020
Last updated 12 January 2021 +show all updates
  1. Added large print version of the letter.

  2. Replaced with latest version and temporarily removed alternative formats.

  3. Removed 2 December letter from Matt Hancock.

  4. Added Letter to clinically extremely vulnerable people in Tier 4: British Sign Language version.

  5. Added large print version of Tier 4 letter.

  6. Added Letter to clinically extremely vulnerable people in Tier 4: audio version.

  7. Added copy of letter sent to clinically extremely vulnerable people in Tier 4.

  8. Added audio version.

  9. Added easy-read, large print and translated versions.

  10. Added YouTube link to British Sign Language version.<

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: